Salam, Shameen
Mallat, Jihad
Elkambergy, Hussam
2020-10-19T20:48:51Z
2020-10-19T20:48:51Z
2020
2213-0071
https://doi.org/10.1016/j.rmcr.2020.101263
http://hdl.handle.net/20.500.12010/14598
Cytokine storm induced by the coronavirus 19 (COVID-19) profoundly activates the coagulation
cascade causing venous thromboembolism (VTE). Initial studies from Wuhan, China showed
increased incidence of VTE in patients with no standard deep vein thrombosis (DVT) prophylaxis
in COVID-19 pneumonia patients. Few have argued for high intensity or intermediate DVT
prophylaxis in COVID-19 patients with the incidence of VTE ranging from 16-27% despite
standard DVT prophylaxis. However, no guideline recommendations presently exist to prescribe
augmented DVT prophylaxis in these patients due to lack of evidence although the risk of VTE
was clearly demonstrated. While there are ongoing trials to demonstrate the efficacy of
intermediate dosing against standard DVT prophylaxis in the prevention of VTE, we present a
36-year-old male admitted with COVID-19 pneumonia who developed acute high-risk
pulmonary embolism (PE) requiring emergent thrombolytic therapy despite intermediate
dosing DVT prophylaxis.
11 páginas
application/pdf
eng
Respiratory Medicine Case Reports
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Pulmonary embolism
COVID-19
Thrombolytic therapy
DVT prophylaxis
Venous thromboembolism
Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/acceptedVersion
Abierto (Texto Completo)
https://doi.org/10.1016/j.rmcr.2020.101263
http://purl.org/coar/resource_type/c_2df8fbb1